To view this email as a web page, click here

Today's Rundown

Featured Story

Merck lands option on Symvivo's oral vaccine delivery platform

Merck has secured an exclusive option to license Symvivo’s bacTRL platform for use in oral vaccine delivery. The research collaboration positions Merck to evaluate a technology that uses engineered bacteria to deliver genetic material.

read more

Top Stories

Teva's long-acting schizophrenia drug hits goal in phase 3

A phase 3 clinical trial of an extended-release formulation of the antipsychotic drug risperidone has met its primary endpoint. The study boosts Teva’s efforts to establish a presence in the market for long-acting injectable treatments for schizophrenia.

read more

Translate Bio targets Q2 data drop on nebulized mRNA therapy

Translate Bio is aiming to deliver data on the first clinical-stage nebulized mRNA therapy early in the second quarter. The biotech set the target after the phase 1/2 cystic fibrosis clinical trial completed enrollment and dosing for the interim analysis. 

read more

COVID-19 nasal spray starts clinical development in the U.K.

U.K. physicians have begun clinical development of a nasal spray designed to prevent infection with the coronavirus and treat mild to moderate cases of COVID-19. The spray delivers nitric oxide into the nasal passages to destroy the virus at a site it uses to enter the body and begin replicating.

read more

Synairgen's inhaled interferon for COVID-19 enhances short, harmless version of virus entry point: study

Interferon increases levels of the cell surface protein ACE2, which serves as the entry point for COVID-19, raising concerns that Synairgen and others developing inhaled interferon-based treatments might ultimately fail. Now, a U.K. team has discovered interferon only raises levels of a short form of ACE2 that may actually be protective.

read more

Resources

Webinar: Using SPOT™ & CHO-BC® During Cell Line Development for Titers up to 9 g/L

Innovative cell lines and early process development are critical to generate a high producing cell lines alongside a USP strategy to meet high quality standards.

Whitepaper: Success in Rare Diseases: Understanding the Rare Disease Ecosystem

Biopharma companies in rare diseases: How to maximize the odds of success by becoming a valued member of the unique “rare disease ecosystem.”

Infographic: 6 Ways Phenotypic Data Improves Decision-Making in Your Drug Development Program

Learn six ways metabolomics provides greater confidence, higher success rates and complements the work of your in-house teams for your drug development pipeline.

Whitepaper: The Future of Pharmacovigilance

Download the whitepaper to learn how your safety organization can implement automation technologies to enable process and cost efficiencies, improve resource allocation and ensure compliance and quality.

Whitepaper: Survey Reveals Demand for Clinical Trial Innovation in the Wake of COVID-19

The BBK Worldwide Study Voices 2020 survey gives voice to the healthcare consumer in the wake of COVID-19 and reveals important insights for clinical trial enrollment and engagement.

Infographic: Reducing Time to Clinic for Your Biomedical Applications

This infographic describes the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Whitepaper: Gene and Cell Therapy: Planning for Manufacturing Success Early

Gene and cell therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations throughout development. In this document, Aldevron provides an in-depth look at preparing for plasmid manufacturing based on our years of experience.

Whitepaper: Companies Need An Effective Remote Workforce Cloud Strategy To Survive

A sound Cloud Strategy provides the flexibility and tools businesses need to quickly adapt and operate securely in an ever-changing remote work environment. Learn how your company can cost-effectively empower its employees to be productive and secure while working remotely.

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Q&A: Planning Successful Launches

Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools.

eBook: CMC Considerations for Successful Early Drug Development

This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success.

Webinar: Phase Appropriate Expertise and Technologies to Accelerate Product Development to Commercialization

In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Whitepaper: The Art of Recognizing Clinical Supply Risk Factors

In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management.

Events